Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug

Company Overview - Travere Therapeutics (TVTX) experienced a significant decline in share price following the announcement of a delay in the FDA approval for its drug Filspari, intended for treating focal segmental glomerulosclerosis (FSGS) [3] - The FDA is now expected to make a decision on Filspari by April 13, which is a postponement from the original date of January [3] Market Reaction - The market reacted negatively to the news, leading to a crash in Travere Therapeutics' shares as investors processed the implications of the delay [3] - Despite the setback, Travere Therapeutics has been highlighted as a stock that has doubled in value in 2025, indicating previous strong performance prior to the announcement [6] Future Outlook - The company is under scrutiny as it approaches the new FDA decision date, with potential implications for its market position and investor sentiment [3][6] - Travere Therapeutics has received a composite rating upgrade, suggesting some analysts still see potential in the stock despite the recent challenges [8]